Standout Papers

Rivaroxaban versus Warfarin in Nonvalvu... 1990 2026 2002 2014 6.5k
  1. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation (2011)
    Manesh R. Patel, Kenneth W. Mahaffey et al. New England Journal of Medicine
  2. Prevalence of Diagnosed Atrial Fibrillation in Adults (2001)
    Alan S. Go, Elaine M. Hylek et al. JAMA
  3. A Prediction Rule to Identify Low-Risk Patients with Community-Acquired Pneumonia (1997)
    Michael J. Fine, Thomas E. Auble et al. New England Journal of Medicine
  4. The Effect of Low-Dose Warfarin on the Risk of Stroke in Patients with Nonrheumatic Atrial Fibrillation (1990)
    Daniel E. Singer New England Journal of Medicine
  5. Estimates of Current and Future Incidence and Prevalence of Atrial Fibrillation in the U.S. Adult Population (2013)
    Susan Colilla, William Petkun et al. The American Journal of Cardiology
  6. Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial Fibrillation (2003)
    Elaine M. Hylek, Alan S. Go et al. New England Journal of Medicine
  7. Antithrombotic Therapy for Atrial Fibrillation (2012)
    John J. You, Daniel E. Singer et al. CHEST Journal
  8. Assessing Health-Related Quality of Life in Patients With Sciatica (1995)
    Donald L. Patrick, Richard A. Deyo et al. Spine
  9. A New Risk Scheme to Predict Warfarin-Associated Hemorrhage (2011)
    Margaret C. Fang, Alan S. Go et al. Journal of the American College of Cardiology
  10. The Relationship Between Daily Atrial Tachyarrhythmia Burden From Implantable Device Diagnostics and Stroke Risk (2009)
    Taya V. Glotzer, Emile G. Daoud et al. Circulation Arrhythmia and Electrophysiology
  11. An Analysis of the Lowest Effective Intensity of Prophylactic Anticoagulation for Patients with Nonrheumatic Atrial Fibrillation (1996)
    Elaine M. Hylek, Steven J. Skates et al. New England Journal of Medicine
  12. Antithrombotic Therapy in Atrial Fibrillation (2008)
    Daniel E. Singer, Gregory W. Albers et al. CHEST Journal
  13. Anticoagulation Therapy for Stroke Prevention in Atrial Fibrillation (2003)
    Alan S. Go, Elaine M. Hylek et al. JAMA
  14. The Clinical Information Value of the Glycosylated Hemoglobin Assay (1984)
    David M. Nathan, Daniel E. Singer et al. New England Journal of Medicine
  15. Oral Anticoagulants vs Aspirin in Nonvalvular Atrial Fibrillation (2002)
    Carl van Walraven, Robert G. Hart et al. JAMA
  16. The Net Clinical Benefit of Warfarin Anticoagulation in Atrial Fibrillation (2009)
    Daniel E. Singer et al. Annals of Internal Medicine
  17. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment (2011)
    Keith A.A. Fox, Jonathan P. Piccini et al. European Heart Journal
  18. Mortality Among Homeless Adults in Boston (2013)
    Travis P. Baggett, Stephen W. Hwang et al. JAMA Internal Medicine
  19. The Unmet Health Care Needs of Homeless Adults: A National Study (2010)
    Travis P. Baggett, James J. O’Connell et al. American Journal of Public Health
  20. Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes (2016)
    Benjamin A. Steinberg, Peter Shrader et al. Journal of the American College of Cardiology
  21. Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) (2014)
    Jonathan L. Halperin, Graeme J. Hankey et al. Circulation
  22. Detection of Atrial Fibrillation in a Large Population Using Wearable Devices: The Fitbit Heart Study (2022)
    Steven A. Lubitz, Anthony Z. Faranesh et al. Circulation
  23. Cardiovascular Disease Projections in the United States Based on the 2020 Census Estimates (2022)
    Reza Mohebi, Chen Chen et al. Journal of the American College of Cardiology

Immediate Impact

2 from Science/Nature 170 standout
Sub-graph 1 of 16

Citing Papers

Applied body-fluid analysis by wearable devices
2024 StandoutNature
Key Issues as Wearable Digital Health Technologies Enter Clinical Care
2024 Standout
2 intermediate papers

Works of Daniel E. Singer being referenced

Detection of Atrial Fibrillation in a Large Population Using Wearable Devices: The Fitbit Heart Study
2022 Standout
Anxiety, Depression, and Adverse Clinical Outcomes in Patients With Atrial Fibrillation Starting Warfarin: Cardiovascular Research Network WAVE Study
2018
and 2 more

Author Peers

Author Last Decade Papers Cites
Daniel E. Singer 32567 12314 11772 431 51.2k
Elliott M. Antman 46958 3721 9335 515 57.8k
Keith A.A. Fox 46242 4689 11912 808 57.9k
Mary Cushman 21673 12836 12909 755 55.3k
Alan S. Go 24729 6307 4797 475 46.0k
Christian Torp‐Pedersen 31274 4897 2968 1.3k 50.3k
Lars Wallentin 47953 5432 14817 733 57.5k
Eugene Braunwald 41820 3935 4435 444 56.1k
Christopher B. Granger 48225 5452 7147 833 62.0k
Eugene Braunwald 49596 6537 7900 687 75.0k
Emelia J. Benjamin 68687 11958 3289 766 98.8k

All Works

Loading papers...

Rankless by CCL
2026